CATALYST PHYSICIAN REGENERATIVE NETWORK ANNOUNCES BIG CORPORATE CHANGES
CAREstream America, a premier product and services...
Catalyst Physician Regenerative Network is pleased to announce our acquisition by CAREstream America, a premier product and services distributor for pain management, regenerative and aesthetic specialties. Read more about this industry-shaping transformation by clicking here.
CAREstream America, a premier product and services...
The test for identifying potential APIC-A2M candid...
It’s always exciting at The Orthobiologic Institut...
Dr. Andrew Konen specializes in pain management at...
August 10, 2016
Source: Stanford University Medical Center
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects. The new procedure could clear the way for patients to receive blood stem cells from donors more safely.
READ MORE
March 10, 2016
Source: University of Edinburgh
People with leukemia could be helped by new research that sheds light on how the body produces its blood supply. Enabling scientists to grow the stem cells artificially from pluripotent stem cells could also lead to the development of personalized blood therapies, researchers say.
READ MORE
November 6, 2015
Source: Forbes.com
Regenerative medicine is one of the fastest growing biomedical industries in the world because patients are being cured of diseases that were once incurable. Regenerative medicine represents a new paradigm in human health because the vast majority of treatments for chronic and life-threatening diseases focus on treating the symptoms, not curing the disease.
READ MORE
August 4, 2016
Source: UC San Diego Health
Robert Legaspi was 9 years old when he was first diagnosed with acute lymphoblastic leukemia (ALL). This year, at age 27, his leukemia returned for the fourth time. This time was different, though — on May 20, 2016, Legaspi became the first patient in San Diego to receive a new type of immunotherapy, known as CAR T-cell therapy, as part of a Phase I/II clinical trial at Moores Cancer Center at UC San Diego Health.
READ MORE